{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:55:52Z","timestamp":1787064952540,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Letermovir, a cytomegalovirus prophylactic agent, is widely used in allogeneic HSCT recipients. As an inhibitor of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), it may interact with ciclosporin A (CsA), potentially impacting its pharmacokinetics. Inflammation can impair CYP3A-mediated drug metabolism, with severe inflammation reducing CsA metabolism. However, current data on the drug\u2013drug interaction (DDI) between CsA and letermovir as a perpetrator are limited to healthy volunteers and lack evaluation in HSCT patients, particularly under minimal inflammation conditions, where such DDIs may occur.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational, single-centre study included seven adult HSCT recipients who received CsA and letermovir concurrently with no-to-mild inflammation (C-reactive protein \u200a\u226440\u2005mg\/L). CsA concentration\/dose (C\/D) ratios were calculated before and after letermovir initiation. Changes in CsA pharmacokinetics were analysed using Wilcoxon signed-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 240\u2005mg dose of letermovir once daily significantly increased the median CsA C\/D ratio from 0.39 to 0.90 (P\u200a=\u200a0.0156) and the median CsA trough concentration from 136\u2005\u00b5g\/L to 240\u2005\u00b5g\/L (P\u200a=\u200a0.0156). These changes were attributed to CYP3A4 inhibition by letermovir, given the stable no-to-mild inflammatory status and the lack of additional DDI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Letermovir significantly decreased CsA metabolism in HSCT patients through CYP3A4 inhibition, with clinical implications for dosing precision. Close therapeutic drug monitoring (generally twice weekly) is therefore recommended during letermovir initiation and discontinuation to mitigate risks of subtherapeutic levels or toxicity. This study highlights the significance of assessing DDIs in HSCT, where inflammation modulates metabolic interactions resulting in a complex interplay such as a disease\u2013drug\u2013drug interaction (D\u2013DDI).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf063","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T15:20:50Z","timestamp":1739892050000},"page":"1269-1273","source":"Crossref","is-referenced-by-count":5,"title":["Drug\u2013drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-852X","authenticated-orcid":false,"given":"David","family":"Malno\u00eb","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire de Rennes, P\u00f4le Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie , Rennes 35033 ,","place":["France"]},{"name":"Facult\u00e9 de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Universit\u00e9 de Rennes , Rennes 35043 ,","place":["France"]},{"name":"CHU Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Sant\u00e9, Environnement et Travail)-UMR_S 1085, Universit\u00e9 Rennes , Rennes F-35000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-4298","authenticated-orcid":false,"given":"Mathilde","family":"Bories","sequence":"additional","affiliation":[{"name":"CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes , Rennes 35000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-2169","authenticated-orcid":false,"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, CHU de Rennes, INSERM U1236, Universit\u00e9 de Rennes , Rennes 35000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-0957","authenticated-orcid":false,"given":"Pascal","family":"Le Corre","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Rennes, P\u00f4le Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie , Rennes 35033 ,","place":["France"]},{"name":"Facult\u00e9 de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Universit\u00e9 de Rennes , Rennes 35043 ,","place":["France"]},{"name":"CHU Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Sant\u00e9, Environnement et Travail)-UMR_S 1085, Universit\u00e9 Rennes , Rennes F-35000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2025050205520778900_dkaf063-B1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2174\/18755453MTE05NDYa1","article-title":"Absorption, metabolism, distribution, and excretion of letermovir","volume":"22","author":"Menzel","year":"2021","journal-title":"Curr Drug Metab"},{"key":"2025050205520778900_dkaf063-B2","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/pharmaceutics14112493","article-title":"Involvement of transporters in intestinal drug\u2013drug interactions of oral targeted anticancer drugs assessed by changes in drug absorption time","volume":"14","author":"Malno\u00eb","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025050205520778900_dkaf063-B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2025050205520778900_dkaf063-B4","doi-asserted-by":"publisher","first-page":"e18636","DOI":"10.7717\/peerj.18636","article-title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ"},{"key":"2025050205520778900_dkaf063-B5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0169-409X","article-title":"Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery","volume":"27","author":"Hebert","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"2025050205520778900_dkaf063-B6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40262-015-0339-2","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogeneic haematopoietic cell transplantation: part I","volume":"55","author":"McCune","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2025050205520778900_dkaf063-B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025050205520778900_dkaf063-B8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/jcph.1423","article-title":"Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil","volume":"59","author":"McCrea","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2025050205520778900_dkaf063-B9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/1078155222","article-title":"Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis","volume":"29","author":"Malespini","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2025050205520778900_dkaf063-B10","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6141","article-title":"Inflammation decreases ciclosporin metabolism in allogeneic hematopoietic stem cell transplantation recipients","author":"Malno\u00eb","year":"2024;","journal-title":"J Clin Pharmacol"},{"key":"2025050205520778900_dkaf063-B11","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2025050205520778900_dkaf063-B12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/FTD.0b013e3181d5881f","article-title":"Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation","volume":"32","author":"Duncan","year":"2010","journal-title":"Ther Drug Monit"},{"key":"2025050205520778900_dkaf063-B13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1060028015577798","article-title":"Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms","volume":"49","author":"Kim","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2025050205520778900_dkaf063-B14","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1111\/bcp.16185","article-title":"Incidence, clinical classification and risk factors of cyclosporin A-induced liver injury in allogeneic haematopoietic stem cell transplant recipients","volume":"90","author":"Lv","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"2025050205520778900_dkaf063-B15","doi-asserted-by":"publisher","first-page":"371.e1","DOI":"10.1016\/j.jtct.2022.03.028","article-title":"Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplantation recipients","volume":"28","author":"Marciano","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025050205520778900_dkaf063-B16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","article-title":"Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal","volume":"115","author":"Nakashima","year":"2022","journal-title":"Int J Hematol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1269\/62201889\/dkaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1269\/62201889\/dkaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T05:52:15Z","timestamp":1746165135000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1269\/8045733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf063","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,28]]}}}